First launches imminent for Lilly/Daiichi Sankyo's antiplatelet drug Efient
This article was originally published in Scrip
Executive Summary
Lilly and Daiichi Sankyo's novel antiplatelet therapy Efient (prasugrel) will be launched in the coming weeks in its first markets, the UK and Germany, after the European Commission approved the drug for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).